The Motley Fool·2025-12-24 08:51Core Viewpoint - Stanley Druckenmiller, the billionaire head of Duquesne Family Office, has shifted his investment focus from AI stocks like Nvidia and Palantir to Teva Pharmaceutical Industries, which has seen a 191% increase in share price since the start of 2024 [1][18]. Group 1: Artificial Intelligence Stocks - Nvidia and Palantir have been significant holdings for many fund managers, with Nvidia reaching a market cap of $5 trillion and Palantir's shares increasing by over 2,900% [7][10]. - Despite their success, Druckenmiller sold his remaining shares in Nvidia (214,060 shares) during the September-ended quarter of 2024 and exited Palantir (769,965 shares) between July 1, 2024, and March 31, 2025 [10][11]. - Concerns exist regarding the sustainability of Nvidia and Palantir's valuations, with Palantir's price-to-sales (P/S) ratio at 127, which is considered unsustainable [16]. Group 2: Teva Pharmaceutical Industries - Teva's shares have surged by 191% since early 2024, and Druckenmiller has been accumulating shares consistently since the second half of 2024, making it the third-largest holding in his fund [18][19]. - The resolution of legal issues related to the opioid crisis has alleviated financial concerns for Teva, allowing a renewed focus on its innovative capabilities [19]. - Teva is shifting towards novel drug development, which is expected to improve pricing power and margins, with the tardive dyskinesia drug Austedo projected to generate over $2 billion in global sales in 2025 [20][21]. - Teva has significantly improved its balance sheet, reducing net debt from over $35 billion to $14.6 billion by the end of Q3 2025 [21][22].